Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “SION”

1,496 pharma patents match "SION" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,496
Index total 30,257
Page 3 / 63

Quick answer

This filtered view shows 1,496 pharmaceutical patents matching "SION" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,496 results for “SION” · 30,257 patents in full index Clear search

  1. US 12291709

    Compositions and methods for modulating apolipoprotein (a) expression

    Ionis Pharmaceuticals, Inc. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  2. US 12291058

    Dispersions for additive manufacturing comprising discrete carbon nanotubes

    MOLECULAR REBAR DESIGN, LLC · Granted May 6, 2025 · Expires May 1, 2045

    granted
  3. US 12280093

    Use of a VEGF receptor-based fusion protein antagonist to treat nonproliferative diabetic retinopathy

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  4. US 12281305

    Compounds and methods for reducing prion expression

    Ionis Pharmaceuticals, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  5. US 12281321

    Frataxin expression constructs having engineered promoters and methods of use thereof

    VOYAGER THERAPEUTICS, INC. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  6. US 12274735

    IL-4-fusion formulations for treatment of central nervous system (CNS) tumors

    Medicenna Therapeutics Inc. · Granted Apr 15, 2025 · Expires Apr 10, 2045

    granted
  7. US 12275758

    Prefusion RSV F proteins and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 15, 2025 · Expires Apr 10, 2045

    granted
  8. US 12268660

    Oral pharmaceutical formulations of bitter compounds for pulmonary hypertension

    Aardvark Therapeutics, Inc. · Granted Apr 8, 2025 · Expires Apr 3, 2045

    granted
  9. US 12259378

    Dynamic clamps and methods of use thereof

    PRAXIS PRECISION MEDICINES, INC. · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  10. US 12247226

    Cellular reprogramming using temporal and transient plasmid vector expression system

    Fate Therapeutics, Inc. · Granted Mar 11, 2025 · Expires Mar 6, 2045

    granted
  11. US 12246059

    Stable hybrid FC fusion G-CSF formulation

    ILKOGEN ILAÇ SANAYI VE TICARET A.S. · Granted Mar 11, 2025 · Expires Mar 6, 2045

    granted
  12. US 12241067

    Compounds and methods for reducing LRRK2 expression

    Ionis Pharmaceuticals, Inc. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  13. US 12233135

    Therapeutic constructs for treating cancer

    PRECISION MOLECULAR INC. · Granted Feb 25, 2025 · Expires Feb 20, 2045

    granted
  14. US 12232492

    Disinfection of bacteriophages products using supercritical carbon dioxide

    PRECISIONBIOTIX TECHNOLOGIES INC. · Granted Feb 25, 2025 · Expires Feb 20, 2045

    granted
  15. US 12228572

    Enhanced expression of polo-like kinase 3 (PLK3) in human immunodeficiency virus (HIV)-infected cells

    The First Hospital of China Medical University · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  16. US 12226437

    Method for enhancing expression of insulin like growth factor 1 receptor in umbilical cord mesenchymal stem cell expressing IGF1R and method for obtaining multipotent umbilical cord mesenchymal stem cell

    China Medical University · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  17. US 12227584

    Multivalent and multispecific OX40-binding fusion proteins

    Inhibrx Biosciences, Inc. · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  18. US 12227744

    Compositions and methods for inhibiting expression of transthyretin

    Alnylam Pharmaceuticals, Inc. · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  19. US 12221610

    RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Feb 11, 2025 · Expires Feb 6, 2045

    granted
  20. US 12221483

    Fusion protein and nucleic acid encoding sequence thereof, and uses of the same

    China Medical University Hospital · Granted Feb 11, 2025 · Expires Feb 6, 2045

    granted
  21. US 12215131

    IgG Fc-IL2-Rα-IL2 fusions and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  22. US 12214218

    Perfusion modulated tumor dose sculpting with single dose radiotherapy

    FUNDAçÃO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  23. US 12208227

    Precision bio-chemotronic system

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted
  24. US 12201673

    Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted